Palatin Technologies Unveils Innovative Findings on Melanocortin Agonists at ARVO 2025 Palatin Technologies has presented groundbreaking preclinical results showcasing the potential of melanocortin agonists PL9654 and PL9655 for diabetic retinopathy treatment.

Palatin Technologies Unveils Innovative Findings on Melanocortin Agonists at ARVO 2025 #United_States #Palatin_Technologies #Diabetic_Retinopathy #Cranbury,_New_Jersey #melanocortin_agonists